



Invitation to the presentation of SenzaGen's Interim Report January–June 2024

Lund, August 15, 2024

SenzaGen's interim report for January-June will be published on August 22, 2024, at 08:30 AM, followed by a live webcast presentation at 10:00 AM on the same day. The presentation will be given by the SenzaGen's President and CEO, Peter Nählstedt, with a subsequent Q&A session moderated by Redeye's analyst Gustaf Meyer.

The presentation will be held in English.

Time: Thursday, August 22, from 10:00 AM to 11:00 AM.

Link to webcast: <https://www.redeye.se/events/1015874/investor-update-senzagen-3>.

The presentation can also be viewed later on SenzaGen's website: <https://senzagen.com/investors/presentations/>.

Contacts

Peter Nählstedt, President and CEO, SenzaGen AB
Email: peter.nahlstedt@senzagen.com | Mobile: +46 700 23 44 31

Tina Dackemark Lawesson, VP Marketing & Communications
Email: tina.lawesson@senzagen.com | Mobile: +46 708 20 29 44

About us

SenzaGen is a corporate group that aims to be a leader in *in vitro* science and testing, driving the transition from animal testing to methods better suited to reflect human biology. The Company provides high-performance, non-animal test methods and innovation and consulting services based on state-of-the-art technology. Non-animal methods are more effective, more accurate and less expensive than traditional animal-based methods while also helping to reduce the number of laboratory animals. The Company has a growth strategy centered around continued commercialization of its proprietary GARD® and VitroScreen ORA® test platforms, expansion of its test portfolio and evaluation of acquisition opportunities of profitable and growing companies with complementary offerings. SenzaGen has its headquarters and GLP-certified laboratory in Lund, Sweden and subsidiaries in the US and Italy. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA). FNCA Sweden AB is the company's Certified Adviser.



Attachments

[Invitation to the presentation of SenzaGen's Interim Report January–June 2024](#)